# US 2026/0091192 A1 · Methods to increase functional capacity and quality of life in bronchietasis patients with nontuberculous mycobacteria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091192 A1
- Document ID: US20260091192A1
- Status: Published application
- Kind: A1
- Application number: 19/413,816
- Filed: 2025-12-09
- Published: 2026-04-02
- Earliest claimed: 2019-05-16
- Assignees: Malllinckrodt Pharmaceuticals Ireland Limited
- Applicants: Malllinckrodt Pharmaceuticals Ireland Limited
- Inventors: James Potenziano; Christopher Miller
- Web page: https://patentgrep.com/patent/US20260091192A1

## CPC

- A61M 16/10: Preparation of respiratory gases or vapours
- A61M 16/12: by mixing different gases
- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61M 16/026: {specially adapted for predicting, e.g. for determining an information representative of a flow limitation during a ventilation cycle by using a root square technique or a regression analysis}
- A61P 11/00: Drugs for disorders of the respiratory system
- C01B 21/24: Nitric oxide (NO) {(C01B21/203 takes precedence)}
- A61M 2202/0275: Nitric oxide [NO]
- A61M 2230/20: Blood composition characteristics
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}

## Abstract

Provided herein are method of treating a patient with nontuberculous mycobacteria by administering nitric oxide to the patient for at least 100 days to increase functional capacity and quality of life of the patient.

## Claims

### Claim 1

A method of treating a patient with nontuberculous mycobacteria with intelligent dosing, comprising:
administering a first amount of nitric oxide gas to the patient for a first period of time;
evaluating one or more intelligent dosing factors selected from the group consisting of blood oxygen content, oxygen dilution, methemoglobin, and methemoglobin reductase; and
administering a second amount of nitric oxide gas for a second period of time based on the one or more intelligent dosing factors.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first amount of nitric oxide gas is greater than the second amount of nitric oxide gas.

### Claim 3 (depends on 1)

The method of claim 1, wherein the first amount of nitric oxide gas is less than the second amount of nitric oxide gas.

### Claim 4 (depends on 1)

The method of claim 1, wherein the one or more intelligent dosing factors includes methemoglobin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first period of time is about 5 minutes to about 100 minutes.

### Claim 6 (depends on 1)

The method of claim 1, wherein the second period of time is about 5 minutes to about 100 minutes.

### Claim 7 (depends on 1)

The method of claim 1, further comprising administering a dose of an antibiotic treatment while administering the first amount of nitric oxide gas and/or the second amount of nitric oxide gas.

### Claim 8 (depends on 7)

The method of claim 7, wherein the dose of the antibiotic treatment is reduced from what would be administered without administration of nitric oxide gas.

### Claim 9 (depends on 1)

The method of claim 1, wherein the first amount of nitric oxide gas is about 80 ppm to about 500 ppm.

### Claim 10 (depends on 9)

The method of claim 9, wherein the first amount of nitric oxide gas is about 80 ppm to about 160 ppm.

### Claim 11 (depends on 1)

The method of claim 1, wherein the second amount of nitric oxide gas is about 80 ppm to about 500 ppm.

### Claim 12 (depends on 11)

The method of claim 11, wherein the second amount of nitric oxide gas is about 200 ppm to about 500 ppm.

### Claim 13 (depends on 1)

The method of claim 1, wherein the two administering steps each occur more than once over a prolonged period of time of at least 5 days.

### Claim 14 (depends on 13)

The method of claim 13, wherein the prolonged period of time is at least 100 days.

### Claim 15 (depends on 13)

The method of claim 13, wherein the prolonged period of time is at least 200 days.

### Claim 16 (depends on 13)

The method of claim 13, wherein the prolonged period of time is at least 300 days.

### Claim 17 (depends on 1)

The method of claim 1, further comprising ceasing administration of nitric oxide gas when an intelligent dosing factor threshold is reached.

### Claim 18 (depends on 1)

The method of claim 1, further comprising evaluating a CRISS score and/or six minute walk performance of the patient.

### Claim 19 (depends on 18)

The method of claim 18, wherein the patient has a reduced CRISS score by 50% after administration of the nitric oxide gas compared to a baseline.

### Claim 20 (depends on 18)

The method of claim 18, wherein the patient has an improved six minute walk performance by at least 10% after administration of the nitric oxide gas compared to a baseline.